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SIMULTANEOUS QUANTITATION OF SERUM HBV DNA AND HBeAg CAN DISTINGUISH 
BETWEEN SLOW AND FAST VIRAL RESPONSES TO ANTIVIRAL  
THERAPY IN PATIENTS WITH CHRONIC HEPATITIS B
Luiz Caetano DA SILVA, Maria Luiza da NOVA, Suzane Kioko ONO-NITA, João Renato Rebello PINHO, Roberta SITNIK, 
Vera Aparecida dos SANTOS & Flair José CARRILHO
SUMMARY
Background: The quantitation of serum HBeAg is not commonly used to monitor viral response to therapy in chronic hepatitis B. 
Methods: In this study, 21 patients receiving varying therapies were followed and their viral response monitored by concomitant viral 
load and HBeAg quantitation in order to study the meaning and the kinetics of both parameters. Results: It was possible to distinguish 
between three different patterns of viral response. The first was characterized by a simultaneous decrease in serum HBV DNA and 
HBeAg. The second pattern was characterized by a decrease in serum HBeAg but persistent detection of HBV DNA. The third pattern 
was characterized by undetectable HBV DNA with persistent HBeAg positivity, which points to a non-response (Pattern III-B) except 
when HBeAg levels showed a slow but steady drop, characterizing a “slow responder” patient (Pattern III-A). Conclusions: The first 
pattern is compatible with a viral response. A long-term HBeAg seropositivity with a slow and persistent decrease (Pattern III-A) is 
also compatible with a viral response and calls for a prolongation of anti-viral treatment.
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INTRODUCTION
The management of chronic hepatitis B has been the subject of many 
reviews over the last few years4,11,19,23,24. Updates to the recommendations 
for monitoring patients infected with hepatitis B virus (HBV) were 
recently published20,25, and in them, as well as recent publications on 
this subject, serum Hepatitis e antigen (HBeAg) is considered only 
qualitatively with no evaluation of its expression (quantitation) as a tool 
for monitoring patients undergoing treatment20,25.
According to KEEFE et al.20, the quantitation of HBeAg has not 
been widely used, is expensive, and available data about the predictive 
value of HBeAg serostatus remains limited. The same authors mention 
that approximately one third of patients with serum HBV DNA levels 
lower than 104 copies will seroconvert, suggesting a close relationship 
between HBV DNA suppression and the likelihood of seroconversion. 
HBeAg-positive chronic hepatitis B, considered as the classical form, is 
characterized by a stable high level viremia (107-1010 HBV copies/mL), 
whereas HBeAg-negative hepatitis B is characterized by a less stable 
and severe viremia, or less than 106 copies/mL30.
Several different types of quantitative assays based on signal or target 
amplification are available for viral DNA, including high sensitivity 
polymerase chain reaction (PCR)-based methods that measure serum 
HBV DNA levels with a wide dynamic range1,25. Nowadays, real-time 
PCR assays are preferably used25.
The maximum HBV DNA viral load detected in patients with chronic 
HBV is not well established and may depend on the quantitative technique 
used to measure it. Thus, CORDEN et al.5 measured HBV DNA with 
the Chiron Amplicor HBV DNA Monitor Assay and found that the viral 
load was between 4X102 and 1.2X109 copies/mL. In HBeAg-positive 
patients, they found HBV DNA levels of up to 109.5 copies/mL. By using 
in-house end-point dilution PCR based on Kaneko’s method17,18, our 
group found levels of up to 3X1012 copies/mL6,8. Also, using real-time 
PCR, HO et al.14 found median levels of 1.5X107 copies/mL, and JARDI 
et al.16 found median a serum HBV DNA viral load of 9.2X108 copies/
mL (range 2.9X105 - 4.8X1011).
For HBeAg-positive chronic hepatitis B patients, the main goals 
for treatment are HBeAg loss, seroconversion to anti-HBe, normalized 
alanine aminotransferase (ALT) levels, and the suppression of viremia 
to undetectable levels25. However, it has been consistently observed that 
lamivudine (LAM) or adefovir dipivoxil (ADV) produces a rapid and 
dramatic decrease in viremia, but a lower proportion of patients exhibit 
serum HBeAg loss30. This important aspect was also emphasized by 
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NEUMANN26. It is worth mentioning that the production of HBeAg is 
not dependent on the formation of HBV DNA, but it reflects the level of 
HBV core/precore gene expression in the liver34.
The role of HBeAg quantitation has already been addressed by 
some authors13,28. PERILLO et al.28 found that the baseline HBeAg 
concentration is the best independent predictor of a patient’s response to 
interferon-alpha (IFN-a) when compared to baseline HBV DNA levels. 
Furthermore, it was observed, in this study and another12,13,that a steep 
decline in the HBeAg concentration during the first weeks of therapy 
was predictive of an antiviral response. A long-term study on the serial 
quantitation of HBeAg demonstrated that a high serum level (> 100 IU/
mL) at week 24 of therapy with peginterferon alpha-2a (Peg-IFN-a2a) 
had an excellent negative predictive value; less than 5% of patients 
achieved HBeAg seroconversion at week 7210. 
During LAM therapy, different types of changing patterns have 
been observed in relation to levels of HBeAg pretreatment, and they 
have been categorized into three groups: “decrescendo” (“falling”), 
“decrescendo-crescendo” (“falling-rising”), and “no changing” or 
“fluctuating”27,31. These patterns determined by serial monitoring during 
LAM therapy allowed the prediction of the treatment response as well 
as early recognition of a viral breakthrough. However, a simultaneous 
determination of HBV DNA was not performed.
It is worth mentioning that, in HBeAg-positive patients, entecavir 
was found to be more potent than LAM and resulted in undetectable 
HBV DNA by PCR in 67% of patients at week 48, compared to 36% of 
patients treated with LAM3. However, the HBeAg seroconversion rate 
was similar in the two groups, 21% and 18%. Despite these interesting 
and valuable observations, serial quantitative determinations of serum 
HBeAg have not been routinely carried out during the last few years and 
have not been mentioned in some recent recommendations20,25.
Using serial quantitative PCR for HBV DNA and a simultaneous 
quantitative HBeAg assay, we previously observed an interesting 
dissociation between HBV DNA and HBeAg in some patients. Our 
aim is to show that a simultaneous decrease in HBV DNA and HBeAg 
levels, in addition to a slow but stepwise decreasing pattern of HBeAg 
levels in some patients, may predict the negative HBeAg response 
despite a very prolonged positive response during antiviral therapy. 
This is particularly important because serum HBV DNA levels may 
decrease to undetectable levels soon after initiating therapy with LAM 
or other drugs8,26,30,34 and can not be used further for monitoring the 
treatment response.
PATIENTS AND METHODS
Patients: Twenty-one HBeAg-positive patients with chronic hepatitis 
B were enrolled in the study (Table 1). Sixteen patients received LAM 
and five patients received IFN-a plus LAM (Table 2). 
In this phase of the study, we detected some patterns of the viral 
response (described below) in 11 of the 16 patients given LAM and in 
four of the five patients given IFN-a plus LAM. 
Nine patients who did not respond to antiviral therapy, and one who 
presented with a relapse after LAM withdrawal, were retreated as shown 
in Table 3. Three patients (5, 6, and 13) had to receive another series of 
therapy after the second trial.
Patient ages varied from nine to 65 years (mean 38 yr) and they 
were studied during a period of 34 to 133 months (Table 1). All patients 
had Hepatitis B surface antigen (HBsAg) in their serum for at least 
six months and detectable HBV DNA. Patients were excluded if they 
were also infected with hepatitis C virus, hepatitis D virus, or human 
immunodeficiency virus (HIV). Patients who withdrew prematurely from 
the study or had only minimal lesions (inactive HBsAg carrier state) were 
also excluded. All patients gave informed consent for the study, which 
was approved by the Institutional Review Board (Hospital das Clínicas 
- University of São Paulo School of Medicine).
Treatment schedules and primary endpoints: Sixteen patients 
received monotherapy with oral LAM at a dose varying from 150 mg to 
300 mg per day for 12 months and 150 mg/day thereafter as previously 
described8. Three out of four patients with liver cirrhosis received 150 
mg/day from the beginning (Table 2). Therapy with IFN-a (3 to 5 MU 
three times a week) plus LAM (150 mg/day) was initially given to four 
patients (Table 2). Another patient was submitted to combined therapy 
with Peg-IFN-a2b and LAM because of high serum levels of HBV DNA 
and HBeAg and a slight increase in ALT. In our experience, patients with 
such baseline values are prone to develop resistance to monotherapy 
with LAM6,8. Such patients were included in the IFN-related group 
(Table 2). Overall, 21 series of antiviral therapy were used during this 
period (Table 2).
Nine LAM-resistant patients with mutations in the YMDD motif of 
polymerase gene, six with M204V, two with M204I, and one patient with 
both, were retreated (Table 3). Adefovir (10 mg/day) was given to three 
patients as a second series and one patient as a third series (Table 3). 
Pegylated interferon (Peg-IFN) was given to five patients, four received 
Peg-IFN-a2b (1.5 μg/kg of body weight) and one patient received Peg-
IFN-a2a (180 μg), all in association with LAM. Finally, tenofovir was 
given at a dose of 300 mg/day to four unresponsive patients as a rescue 
drug.
As for the two patients who experienced a relapse after withdrawal 
of LAM, one (patient 2) presented with a spontaneous absence of serum 
Table 1
Demographic and baseline data for naïve patients (first phase)
Sex (M/F) 16/5
Age (years) 9 - 65 (± 38)
Caucasians/Asians 14/7
HBV DNA (log) 5.41 - 12.48 (± 9.26)
ALT (xUNL) 0.7 - 8.8 (± 3.24)
Chronic hepatitis/Liver cirrhosis 16/5
First therapy No. of patients
         Lamivudine (LAM) 16
         IFN + LAM 5
Follow-up (months) 34 - 133 (± 91)
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HBeAg but had a persistence of HBV DNA during the non-treatment 
period and received a second series of LAM with subsequent clearance 
of the HBV DNA. The other patient (patient 9) was treated with Peg-IFN-
a2b plus LAM and presented with an HBsAg/anti-HBs seroconversion. 
Finally, another patient non-responder to LAM (patient 16) received LAM 
associated to lobucavir as a rescue drug (withdrawn from the market).
As shown in Table 3, more than two therapeutic series had to be used 
in three patients (patients 5, 6, and 13). Overall, 15 series of antiviral 
therapy were used in the retreatment, resulting in a total number of 36 
therapeutic series for the two phases. The primary endpoints were an 
inability to detect HBV DNA and the loss of HBeAg with seroconversion 
to anti-HBe.
Table 2
Demographic, baseline data, and patterns of HBV DNA and HBeAg responses to initial therapy with lamivudine (LAM) in 16 patients or interferon-alpha (IFN-a) 
plus LAM in five other patients with chronic hepatitis B (CH) or liver cirrhosis (LC)
Patient/ 
Diagnosis Age/Sex
HBV DNA 
(log)
ALT*
(xUNL)
First 
therapy
Viral response 
(VR) / 
(Mutation)**
Pattern Follow-up (months) Outcome
1/CH 37/M 10.48 4.5 LAM VR / (NO) I 102 Seroconversion 
HBsAg/anti-HBs
2/CH 37/F 6.48 8.8 LAM VR / (NO) I 125 Relapse
Re-treatment
3/CH 45/M 8.63 2.3 LAM VR / (M204V) 
(late)
I 125 Breakthrough (late)
Re-treatment
4/LC 65/M 12.48 6.9 LAM VR / (NO) I 109 Seroconversion 
HBsAg/anti-HBs
5/CH 48/M 8.48 1.7 LAM BT / (M204V) II 109 Breakthrough
Re-treatment
6/LC 52/M 8.48 1.5 LAM BT / (M204V/I) II 108 Breakthrough
Re-treatment
7/LC 42/M 10.48 3.1 LAM VR / (NO) IIIA 90 Seroconversion 
HBeAg/anti-HBe
8/LC 59/M 7.96 8.7 LAM VR / (NO) IIIA 48 Seroconversion 
HBeAg/anti-HBe
9/CH 62/M 12.48 1.7 LAM VR / (NO) IIIA 83 VR with relapse
Re-treatment
10/CH 9/F 8.48 3.3 LAM BT / (M204I) IIIB 37 Breakthrough. 
Drop out
11/CH 34/M 5.41 2.0 LAM BT / (M204I) IIIB 95 Breakthrough
Re-treatment
12/CH 11/M 10.48 0.7 LAM NR / (M204I) NR 133 Re-treatment
13/CH 30/M 8.48 2.9 LAM NR / (M204V) NR 117 Re-treatment
14/CH 43/M 10.48 1.7 LAM NR / (M204V) NR 86 Re-treatment
15/CH 44/M 10.48 1.2 LAM NR / (M204V) NR 119 Re-treatment
16/CH 49/M 9.48 8.0 LAM NR / (M204V) NR 103 Breakthrough
Re-treatment
17/CH 29/M 12.48 1.5 IFN+LAM VR / (NO) I 85 Seroconversion 
HBeAg/anti-HBe
18/CH 21/M 6.48 4.2 IFN+LAM VR / (NO) I 34 Seroconversion 
HBeAg/anti-HBe
19/CH 32/F 7.60 2.0 Peg+LAM
***
VR / (NO) IIIA 72 Seroconversion 
HBeAg/anti-HBe
20/LC 11/F 6.40 0.7 IFN+LAM VR / (NO) IIIA 62 Seroconversion 
HBeAg/anti-HBe
21/CH 12/M 8.70 0.7 IFN+LAM NR / (NO) NR 60 Under treatment.
Steady drop of 
HBV DNA and HBeAg
HBV, Hepatitis B virus; HBeAg, Hepatitis e antigen. * XUNL = upper normal limit; ** VR = viral response (PCR negativation); NR = non-response; *** see text.
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Laboratory methods: Serum samples were available for study at 
the following time points: initial screening (“baseline”), every three 
to six months during therapy, and after the completion of therapy. The 
levels of ALT, HBV DNA, and HBeAg were available at each time 
point. The serum ALT levels were tested using commercially available 
assays (Abbott Laboratories). Results are expressed as values times the 
upper normal limit (x UNL). The semi-quantitation of serum HBeAg 
was performed prospectively and simultaneously with the determination 
of serum HBV DNA. Because no commercial assay was available 
for measuring the HBeAg concentration, a micro-particle enzyme 
immunoassay (MEIA, AxSYM HBe 2.0, Abbott Laboratories, Abbott 
Park, IL) was used13. The assay is based on two different monoclonal 
antibodies, and its reference preparation for quantitation of HBeAg 
makes use of purified recombinant HBeAg as a control. Results are 
expressed as an index (sample to cutoff = S/CO) luminescent values 
ratio27.
In 17 patients, the quantitation of HBV DNA was performed by in-
house PCR based on Kaneko’s method17,18 and as previously described6,8. 
The sensitivity of the method was reported to be 3x102 copies/mL, and 
its dynamic range went up to 3x1012 copies/mL. Quantitative results were 
estimated based on end-point dilutions. In the last four patients (patients 
18 to 21), the serum HBV DNA was determined by the Cobas Amplicor 
HBV Monitor Test (Roche Diagnostics, Branchburg, NJ) with a linear 
range from 4x102 (lower limit of detection) to 4x107 copies/mL27. We 
have recorded the HBV-DNA levels in copies/mL instead of IU/mL as 
recently reported19. 
A virologic response was defined as a decrease in serum HBV 
DNA to undetectable levels by PCR and a loss of HBeAg25. Patients 
who showed neither of these serological features were considered to be 
non-responders, and those who presented with only one type of response 
(HBV DNA or HBeAg) were classified according to the patterns as 
described below. A sustained response was defined as the persistence 
of a virologic response for six months after the discontinuation of 
therapy25. The clearance of HBeAg and HBsAg was defined as the 
absence of the particular antigen in two consecutive samples at least 
one month apart. Viral polymerase, precore/core, and surface genes 
were sequenced to determine mutations in the YMDD domain as 
previously described8,32.
Liver biopsies: Liver biopsy was performed with a Tru-cut (Baxter 
Health Care, Deerfield, IL, USA) needle in 20 out of 21 patients. The 
exception was a cirrhotic patient with ascitis and very low platelet counts.
RESULTS
Demographic and baseline characteristics of patients: The 
demographics, baseline data, and patterns of initial therapeutic response 
for the patients studied are shown in Tables 1, 2, and 3. Changes in 
the HBeAg/anti-HBe system were observed in 15/21 patients, and the 
behavior of serum HBeAg expression during a long-term follow-up will 
be further detailed.
As shown in Table 2, a relapse after withdrawal, viral breakthrough, 
Table 3 
Patterns of HBV DNA and HBeAg responses in chronic hepatitis B patients previously resistant to lamivudine (LAM)*  
and submitted to a second or a third anti-viral therapy
Patient ** Type of previous  
resistance
Antiviral therapy  
(re-treatment)
Pattern of response*** Outcome
2/CH Relapse Lamivudine**** I HBeAg/anti-HBe seroconversion
3/CH M204V Adefovir NR Late HBVDNA negativation and late 
HBeAg/anti-HBe seroconversion
5/CH M204V PegIFN-a2b+Lamivudine I Viral response with relapse
Adefovir IIIB HBeAg-non-response
Tenofovir IIIA Profound drop of HBeAg
6/LC M204V/M204I PegIFN-a2b+Lamivudine NR HBVDNA persistently positive
Tenofovir *** Clearance of HBVDNA (See table 2)
9/CH Relapse PegIFN-a2b+Lamivudine I HBsAg/anti-HBs seroconversion
11/CH M204I Adefovir IIIB Breakthrough
12/CH M204I Tenofovir IIIA Under treatment
13/CH M204V PegIFN-a2b+Lamivudine I VR with relapse
Tenofovir I Under treatment
14/CH M204V Adefovir I Under treatment
15/CH M204V PegIFN-a2a+Lamivudine I HBeAg/anti-HBe seroconversion
16/CH M204V Lamivudine+Lobucavir I HBsAg/anti-HBs seroconversion
HBV, Hepatitis B virus; HBeAg, Hepatitis e antigen. * See Table 1; ** No. according to Table 2; *** NR = non-response; undetectability of HBeAg just before teno-
fovir; **** See text.
DA SILVA, L.C.; NOVA, M.L.; ONO-NITA, S.K.; PINHO, J.R.R.; SITNIK, R.; SANTOS, V.A. & CARRILHO, F.J. - Simultaneous quantitation of serum HBV DNA and HBeAg can distinguish 
between slow and fast viral responses to antiviral therapy in patients with chronic hepatitis B. Rev. Inst. Med. trop. S. Paulo, 51(5): 261-268, 2009.
265
or non-response was detected in 13/21 (61.9%) patients and in 12/16 
(75.0%) patients receiving monotherapy with LAM. Sequencing the 
YMDD motif in non-responders receiving LAM revealed the M204V 
mutation in six patients, the M204I mutation in three, and a mixed 
M204V/I mutation in one patient (Table 2). All but one patient (patient 
10) were submitted to re-treatment as stated in Methods (Table 3).
Simultaneous analysis of HBV DNA and HBeAg and characterization 
of decay patterns: The main goal of our study was to describe the response 
of HBV to treatment by comparing the patterns of HBV DNA and HBeAg 
decreases. The results from treated and retreated patients were analyzed 
together. Overall, 36 series of therapy were obtained.
Three different response patterns could be characterized in our 
patients: Pattern I was characterized by a simultaneous decrease in serum 
HBV DNA and HBeAg levels until they were absent within a period of 
six months (Fig. 1A). If the absence of HBV DNA was followed by the 
loss of HBeAg in a maximum period of six months, the pattern was still 
considered as Pattern I.
A concomitant decrease in HBV DNA and HBeAg was observed 
in 13/36 (36.1%) series as shown in Tables 2 and 3. An example of this 
pattern is shown in Fig. 1A for patient 15, who had previous resistance 
to LAM due to the M204V mutation and an excellent response to a 
combined therapy with Peg-IFN-a2a (180 μg per week) and LAM. 
Pattern I during LAM or interferon plus LAM was detected in 4/16 
patients (15%) and 6/10 patients (60%), respectively (p = 0.10, two- 
tailed Fisher exact test).
Pattern II was characterized by the persistence of viremia (HBV DNA 
levels above 1,000 copies/mL) simultaneous with undetectable HBeAg 
(Fig. 1B) for a period greater than six months. 
This pattern was observed in 2/36 (5.6%) series. In one patient 
(patient 5), this pattern was detected during 10 months of therapy with 
Fig. 1 - Viral kinetics in chronic hepatitis B patients. (A) Patient 15, 44 year old male previously resistant to lamivudine (LAM) with a M204V mutation. He exhibited a simultaneous decrease 
leading to undetectable HBV DNA and HBeAg levels (Pattern I) and sustained HBe-Ag/anti-HBe seroconversion after the administration of combined therapy (Peg-IFN-a2a + LAM). (B) 
Patient 5, 48 year old male exhibiting a rapid decrease in HBeAg levels but persistent HBV DNA (Pattern II) followed by a breakthrough during therapy. (C) Patient 19, 32 year old female 
who was treatment-naïve and exhibited a rapid decrease in viremia, a slow decrease in HBeAg (still positive at 24 months), and eventual HBeAg/anti-HBe seroconversion at month 26 (Pattern 
III-A). (D) Patient 11, 34 year old male with persistent levels of HBeAg despite the loss of HBV DNA shown by PCR. He exhibited a breakthrough during LAM administration (Pattern III-B 
can be observed in both series of therapy). LD (limit of detection) for HBVDNA (*) and HBeAg (**).# “Decrescendo-crescendo” (“Falling-rising”) pattern of HBeAg levels*, ** = see Fig. 
1A. Hatched bars represent serum HBV DNA levels above LD and open bars represent HBVDNA levels below LD. Open circles represent HBeAg+, filled circles represent HBeAg-. HBV, 
Hepatitis B virus; HBeAg, Hepatitis e antigen.
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LAM, but HBeAg became positive thereafter (Fig. 1B). In another patient 
(patient 6), a loss of HBeAg was observed during therapy with LAM 
and persisted to be negative throughout despite the high levels of HBV 
DNA over three years. However, a clearance of serum HBV DNA was 
detected three months after the administration of tenofovir. 
Pattern III was characterized by the persistence of detectable HBeAg 
despite the absence of HBV DNA for a period greater than six months. In 
some of these patients, a slow but steady decline of HBeAg was observed 
and was referred to as Pattern III-A (Fig. 1C). 
In other patients, HBeAg decreased followed by an increase in serum 
levels, or it did not change at all, despite the absence of HBV DNA and 
was referred to as Pattern III-B (Fig. 1D).
The absence of HBV DNA preceding the loss of HBeAg for more 
than six months was observed in 11/36 therapeutic series (30.6%).
Pattern III-A was observed in seven patients. Prolonged periods of 
HBeAg positivity with continuously decreasing levels indicate a good, 
but slow, viral response (Fig. 1C). One patient (No. 19) with chronic 
hepatitis B, very high viremia (above 4x107 copies/mL by the Amplicor 
Monitor technique), and a high level of HBeAg was submitted to a 
combined therapy with Peg-IFN-a2b and LAM. As seen in Fig. 1C, 
HBV DNA became undetectable at the third month. A slow but steady 
decrease of HBeAg was observed.
Pattern III-B was observed in the other four patients, all of them 
presenting a viral relapse (Fig. 1D). As seen in Tables 2 and 3, HBeAg/
anti-HBe seroconversion was detected in 5/6 patients who exhibited 
Pattern III-A, whereas no viral response was seen in the four patients 
exhibiting Pattern III-B.
In non-responder patients with persistent serum HBV DNA and 
HBeAg, and in patients presenting with Pattern III-B, the levels of HBeAg 
varied widely either in a “falling-rising” (“decrescendo-crescendo”) 
pattern or with fluctuating values27,31.
The small number of patients in each group did not allow a statistical 
comparison among the different patterns. 
In one patient, all three patterns of viral response were observed, 
as seen in Fig. 2.
The ALT levels varied widely independently of the described patterns 
and were not included in this analysis. 
DISCUSSION
Based on the simultaneous quantitative determinations of serum 
HBV DNA and HBeAg, our results suggest that the HBV kinetics can 
vary widely, depending on the antiviral drugs used for the treatment of 
HBeAg-positive patients with chronic hepatitis B. The kinetics of HBV 
have been investigated, but some problems still need clarification22,26.
Our results suggest that patients with positive HBeAg levels are less 
responsive to LAM or adefovir than combined therapy with interferon 
and LAM or tenofovir. Thus, Pattern I, which is characterized by the 
simultaneous decrease of HBV DNA and of HBeAg in a maximum 
period of six months, is more frequently found during treatment with 
interferon plus LAM or during tenofovir treatment. This pattern presents 
a favorable evolution in most cases, though a relapse or breakthrough 
is occasionally found. Pattern II was detected in very few cases and 
must be investigated with a larger number of patients. In our patients a 
breakthrough was found.
Our patients were followed for periods of time varying from 34 
months to 133 months. Such long periods allowed us to observe that 
different patterns of serum HBeAg changes can be present in the same 
patient, and it allowed us to note how unpredictable the outcomes of 
patients on and off antiviral therapy are7. Despite the role of HBV 
DNA quantitation, the rapid and dramatic decrease in viremia after the 
introduction of nucleoside analogues reinforces the necessity to quantify 
HBeAg levels during the period of HBeAg positivity as an additional 
marker for monitoring responses. In some patients, a progressive drop in 
HBeAg levels may be paralleled with an HBV DNA decrease (Pattern I), 
but in other patients, the decrease of HBeAg is steady and slow, pointing 
to a late response (Pattern III-A)
A progressive decrease in serum HBeAg has been referred as a 
“decrescendo” (“falling”) pattern and a decrease in HBeAg followed by 
a return to high levels as a “decrescendo-crescendo” (“falling-rising”) 
pattern27,31. The first pattern is predictive of a viral response, whereas most 
of the patients who fail to show a continuous decrease in HBeAg levels 
present with a viral breakthrough or non-response. The characteristics of 
our study do not allow for a close comparison with the above-mentioned 
patterns.
Possibly an immune-modulating protein, HBeAg is a nonstructural 
secreted protein translated from HBV e (precore and core) mRNA. 
On the other hand, HBcAg, the major protein of the HBV capsid, is 
translated from HBV pregenomic mRNA21. Since HBeAg and HBcAg 
share a sequence consisting of 149 amino acids, they are collectively 
called Hepatitis B core-related antigens. The measurement of these 
antigens would be particularly useful for monitoring the decline of viral 
Fig. 2 - The appearance of four different patterns in the same patient during different series 
of therapy. Patient 5, 48 year old male presented initially with persistence of HBV DNA 
under lamivudine (LAM) treatment despite the temporary clearance of HBeAg (Pattern II). 
Patterns II, I, III-B, and III-A emerged during LAM,Peg-IFN-a-2b+LAM, adefovir, and 
tenofovir treatment (arrows), respectively. HBV, Hepatitis B virus; HBeAg, Hepatitis e antigen.
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translation activity. It would also allow for a comparison of the efficacies 
of potent antiviral drugs when a large proportion of patients have HBV 
DNA below the detection threshold21. ROKUHARA et al.29 reported that 
five out of six patients treated with LAM for six to eight months still had 
detectable levels of core-related antigen. A similar result was also seen 
in another study34 after 48 weeks of nucleoside analogue therapy; 65% 
of the patients who had undetectable serum HBV DNA (< 300 copies/
mL) still had detectable core-related antigen.
Persistent and steady levels of HBeAg for a prolonged period of 
time, despite the absence of HBV DNA (Pattern III-B) may indicate 
some degree of resistance and herald a breakthrough, as was observed 
in some of our patients. This observation led us to switch adefovir for 
tenofovir in one patient, and a sharp decrease of HBeAg was observed 
(Fig. 2). On the other hand, a progressive decrease in HBeAg points to 
a favorable response, even when the persistence of HBeAg is as long as 
26 months of therapy. As seen in Fig. 1C, such a long-term persistence 
might lead to a withdrawal of the combined therapy of Peg-IFN and LAM. 
As could be predicted by the trend of Pattern III-A in these patients, the 
loss of HBeAg and seroconversion to anti-HBe was a late event during 
this therapy. 
Previous results6 had also showed that a non-response to LAM 
is mainly observed in patients with high viremia, and most of them 
were positive for HBeAg. This correlation was so significant that a 
proportion between the probability of non-response and an increase 
in the logarithm of genome copies per mL could be established. The 
above-mentioned differences in viral dynamics are not surprising as 
nucleotide analogues produce a decrease in viral load mainly through a 
block of viral replication, whereas interferon acts directly through some 
intracellular antiviral pathways and indirectly through a modulation of 
the immune system.
Daily LAM doses of 300 mg may lead to an earlier9,15 and more 
profound suppression of HBV DNA15. In a previous paper, we showed 
a rapid decrease in serum HBV DNA in 27 out of 29 patients (93%) 
whose quantitation was performed after 12 weeks of LAM treatment6. 
This response was demonstrated by three different quantitative methods: 
endpoint dilution, Amplicor-Monitor (Roche), and branched DNA. The 
endpoint dilution method using 10-fold serial dilutions was also used 
by YOTSUYANAGI et al.35 Our data suggests that combination therapy 
with PEG-IFN and LAM usually produces a concomitant decrease of 
HBeAg and HBV DNA, whereas monotherapy with LAM or adefovir 
may produce a rapid decrease in HBV DNA, but result in a slow, or lack 
of, decrease of HBeAg in some patients.
Studies in patients with chronic hepatitis B have reported conflicting 
results regarding the benefits of combining IFN-a or PEG-IFN and LAM, 
and the role of such combinations in chronic hepatitis B treatment requires 
further clarification. According to TER BORG et al.33, the HBV DNA 
decline after 52 weeks of therapy was significantly higher in patients 
undergoing combined therapy (PEG-IFN plus LAM) compared to those 
undergoing monotherapy with PEG-IFN.
The most important limitation of this study relates to the small 
number of patients and therapeutic series. Despite these limitations, our 
study provides some evidence that the decrease in serum HBV DNA 
accompanied by a steady decrease in HBeAg (Pattern I), even when it is 
slow (Pattern III-A), points to a favorable outcome. As was also recently 
proposed for hepatitis C patients2, the use of customized treatment for 
each patient may increase the likelihood of a response, and following up 
on HBV DNA and HBeAg levels helps in choosing the best treatment 
for each patient as well in predicting treatment response. It must be 
emphasized that stopping rules based on HBV DNA determination for 
PEG-IFN treatment could not be established10. Furthermore, our data 
suggests that the period of 48 weeks for the discontinuation of PEG-IFN 
may be too short in some patients.
In conclusion, three different patterns can be observed for HBV DNA 
and HBeAg levels over time when quantitative PCR and HBeAg (MEIA 
AxSYM) techniques are used simultaneously. A more detailed study with 
different therapy schedules and using both methods in a large number of 
patients with chronic hepatitis B is urgently needed.
RESUMO
A quantificação simultânea do DNA VHB e do AgHBe séricos 
podem distinguir entre resposta viral lenta e rápida à terapêutica 
anti-viral em pacientes com hepatite crônica B
Introdução: A quantificação do AgHBe sérico não é habitualmente 
utilizada para monitorizar a resposta viral ao tratamento da hepatite 
crônica B. Métodos: Neste estudo, 21 pacientes sob tratamento com 
diferentes terapias foram acompanhados e a resposta viral monitorizada 
pela quantificação concomitante da carga viral e do AgHBe a fim de 
investigar o significado e a cinética de ambos os parâmetros. Resultados: 
Distinguiram-se três diferentes padrões de resposta viral. O primeiro 
caracterizou-se pela redução simultânea do HBV DNA e AgHBe séricos. 
O segundo padrão caracterizou-se por uma redução do AgHBe porém 
com detecção persistente do HBV DNA. O terceiro padrão caracterizou-
se por HBV DNA indetectável com positividade persistente do AgHBe, 
sugerindo ausência de resposta (Padrão III-B), exceto quando os níveis 
de AgHBe mostraram uma queda lenta porém persistente, caracterizando 
um “respondedor lento” (Padrão III-A). Conclusões: O primeiro padrão 
é compatível com resposta viral. Uma seropositividade prolongada do 
AgHBe porém com uma redução lenta e persistente (Padrão III-A) é 
também compatível com resposta viral, sugerindo o prolongamento do 
tratamento anti-viral.
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